Is Alpha-2-Macroglobulin legal in the United Kingdom?

A broad-spectrum plasma protease inhibitor sold as a knee injection. The one randomised trial in 75 people found it no better than platelet-rich plasma or a steroid, and the authors concluded the extra cost is not justified.

Alpha-2-macroglobulin is a large plasma protein that traps and inactivates a wide range of proteases. Two separate interests converge on it.

Mechanism: Established human biochemistry: A2M is a tetrameric plasma glycoprotein that traps proteases of all four catalytic classes in a bait-and-trap conformational change, then clears the complex through the LRP1 receptor. The joint injection rationale is that it inhibits the matrix-degrading enzymes implicated in cartilage breakdown, and a 2024 minipig study reported that A2M reduced post-traumatic cartilage damage by inhibiting inflammatory pathways.

Regulatory history: No alpha-2-macroglobulin product is FDA approved for any indication. Injections offered in orthopaedic practice are prepared from the patient's own blood at the point of care. No approval exists for any ageing or longevity use.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Alpha-2-Macroglobulin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.